Short interest for Elicio Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Elicio Therapeutics's stock. Short interest data is updated every two weeks.

Elicio Therapeutics Stock (NASDAQ:ELTX), Short Interest Report

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

BENZINGA VIRTUAL HEALTHCARE SUMMIT 2024

Health Care

Events

CSE:BHSC

ELTX

MNTL

ZVSA

The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don&#39;t miss out on this must-attend event!

Benzinga&#39;s 2024 Virtual Healthcare Summit: What&#39;s Next In Health?

Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy 

Biotech

Penny Stocks

General

A clinical-stage biotechnology company has published promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). 

 

Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy

First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P 

A phase 2 trial by a clinical-stage biotechnology company is kicking into full gear. 

First Patient Dosed In Phase 2 Study Of Elicio Therapeutics&#39; ELI-002 7P

Elicio Therapeutics Inc

Needham analyst Scott Berg maintains CS Disco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAW#NYSE">LAW</a>) with a Buy and lowers the price target from $15 to $11.

News

Price Target

Analyst Ratings

Needham Maintains Buy on CS Disco, Lowers Price Target to $11

Anglogold Ashanti Says Q1 Gold Production Up +2% YoY, Fourth Quarter Gold Production Expected To Be The Strongest Quarter This Year

Twitter (now rebranded as X) co-founder Jack Dorsey has acknowledged that the platform&#8217;s business model was the root <a href="https://www.benzinga.com/government/23/05/32612461/elon-musk-retorts-sharply-to-twitter-censorship-accusations-youre-such-a-numbskull">cause of its censorship issues</a>.
What Happened: In an <a href="https://www.piratewires.com/p/interview-with-jack-dorsey-mike-solana">interview</a> with journalist Mike Solana that was published on Thursday, Dorsey was asked that despite his efforts with Bluesky, Nostr, and the public statements, many people still perceive him as the &#8220;<a href="https://www.benzinga.com/news/23/06/32663451/musk-agrees-with-dorsey-that-twitter-was-impossible-to-reform-but-doesnt-regret-paying-outrageously">face of censorship&#8221; at Twitter 1.0</a>.
In response, Dorsey admitted that the <a href="https://www.benzinga.com/news/23/07/33091684/jack-dorsey-says-running-twitter-is-hard-hopes-musk-will-utilize-open-protocols-like-bitcoin">advertising-based business model</a> was the &#8220;core, critical sin&#8221; that led to the censorship problems on Twitter. &#8220;I think the core, critical sin was choosing the advertising model to begin with,&#8221; he stated. 
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/05/38720217/wedbush-analyst-dan-ives-says-the-world-is-in-early-stages-of-a-fourth-industrial-revolution-and-it?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Wedbush Analyst Dan Ives Says The World Is In &#8216;Early Stages Of A Fourth Industrial Revolution&#8217; And It Is Led By Nvidia CEO Jensen Huang As &#8216;Godfather Of AI&#8217;</a>
Dorsey went on to say brand advertising differs from direct advertisement, as it relies less on programmatic approaches. Instead, it often necessitates a significant endorsement from influential entities like Disney, as they prioritize partnerships with major players such as Google and Facebook. &#8220;Snapchat, Twitter, everything else did&nbsp;not matter.&#8221;
&#8220;And these are ads that&nbsp;are essentially throwaway for them.&nbsp;But we made that choice&nbsp;in order to go public,&#8221; he added. 
The Twitter co-founder also mentioned that the company&#8217;s dependency on advertising led to a decline in growth and ad revenue, which in turn made them vulnerable to the demands of major advertisers like P&amp;G and Unilever.
&#8220;And when you&#8217;re entirely dependent on that, if a brand like P&amp;G or Unilever doesn&#8217;t like what&#8217;s happening on the platform, and they threaten to pull the budget, which accounts for like 20% of your revenue? You have no choice, and&#8230; you have no choice,&#8221; he said.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: This is not the first time Dorsey has publicly addressed the challenges of running Twitter. Last year, he&nbsp;<a href="https://www.benzinga.com/news/23/07/33091684/jack-dorsey-says-running-twitter-is-hard-hopes-musk-will-utilize-open-protocols-like-bitcoin">acknowledged the difficulties</a>&nbsp;of managing the platform, saying, &#8220;Running Twitter is hard. I don&#8217;t wish that stress upon anyone.&#8221;
Dorsey has faced criticism from both users and lawmakers. In a&nbsp;<a href="https://www.benzinga.com/news/20/10/18102797/dorsey-defends-twitter-censorship-to-congress-our-team-made-a-fast-decision">congressional hearing in 2020</a>, he defended Twitter&#8217;s decision to limit the spread of a controversial New York Post article, stating, &#8220;Our team made a fast decision,&#8221; adding, &#8220;The enforcement action, however, of blocking URLs both in tweets and in DMs, in direct messages, we believe was incorrect.&#8221;
Meanwhile, during the interview, Dorsey also revealed the <a href="https://www.benzinga.com/24/05/38750990/jack-dorsey-says-he-left-twitter-alternative-he-helped-create-because-it-was-literally-repeating-all">motivations behind his departure</a> from Bluesky, the decentralized social media platform he co-founded as an alternative to Twitter. He said Bluesky was &#8220;literally repeating all the mistakes [Twitter] made as a company.&#8221;
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/news/24/05/38723527/elon-musk-agrees-meta-cant-be-trusted-after-zuckerberg-led-social-media-giant-hit-with-37m-fine-over?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Agrees &#8216;Meta Can&#8217;t Be Trusted&#8217; After Zuckerberg-Led Social Media Giant Hit With $37M Fine Over Data Sharing Practices</a>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo by Frederic Legrand &#8211; COMEO on Shutterstock

Social Media

Tech

Media

Jack Dorsey Explains Why He Continues To Face Criticism As 'Face Of Censorship' Despite Efforts At Bluesky And Nostr: 'I Think The Core, Critical Sin Was Choosing…'

Honda Motor Projects FY25 Revenues of JPY20,300B, Down 0.6% YoY; Sees EPS Of JPY210.23, With Operating profit Of JPY1,420B Up 2.8% YoY

Li-Cycle Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.13) by 484.62 percent. The company reported quarterly sales of $4.200 million which missed the analyst consensus estimate of $5.808 million by 27.68 percent. This is a 16.67 percent increase over sales of $3.600 million the same period last year.

Earnings

Earnings Misses

LICY

Li-Cycle Holdings Q1 2024 GAAP EPS $(0.76) Misses $(0.13) Estimate, Sales $4.200M Miss $5.808M Estimate

TD Cowen analyst Andrew Charles maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Hold and raises the price target from $22 to $26.

TD Cowen Maintains Hold on Sweetgreen, Raises Price Target to $26

Needham analyst Mike Cikos maintains JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) with a Buy and lowers the price target from $55 to $45.

FROG

Needham Maintains Buy on JFrog, Lowers Price Target to $45

Costamare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) reported quarterly earnings of $0.63 per share which missed the analyst consensus estimate of $0.65 by 3.08 percent. This is a 65.79 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $470.172 million which beat the analyst consensus estimate of $383.317 million by 22.66 percent. This is a 89.00 percent increase over sales of $248.769 million the same period last year.

Earnings Beats

CMRE

Costamare Q1 2024 Adj EPS $0.63 Misses $0.65 Estimate, Sales $470.172M Beat $383.317M Estimate

<ul>
<li>Adjusted EBITDA of approximately&nbsp;$30 million&nbsp;to&nbsp;$35 million, representing an increase of&nbsp;67%&nbsp;versus 2023 Adjusted EBITDA, measured at the midpoint.</li>
</ul>

Guidance

MOND

Mondee Holdings Sees FY24 Net Revenues Of Approximately $250M-$260M Vs. $251.97M Estimate, Representing An Increase Of 14%

Offerings

Eariler: AHI Received Delisting Notification From Nasdaq For Equity Deficiency, Plans To Appeal And Address $1.15M Shortfall With Oakley Capital's $1.96M Placement And US Shelf Offering

TD Cowen analyst Andrew Charles upgrades Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) from Hold to Buy and raises the price target from $33 to $46.

Upgrades

BROS

TD Cowen Upgrades Dutch Bros to Buy, Raises Price Target to $46

National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) reported quarterly Adj&nbsp;earnings of $0.97 per share. This is a 22.78 percent increase over earnings of $0.79 per share from the same period last year. The company reported $297.18 million in sales this quarter. This is a 10.24 percent increase over sales of $269.56 million the same period last year.

National Healthcare Q1 Adj EPS $0.97 Up From $0.79 YoY, Sales $297.18M Up From $269.56M YoY

Mondee Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOND#NASDAQ">MOND</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.10) by 50 percent. This is a 114.29 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $58.02 million which beat the analyst consensus estimate of $55.23 million by 5.05 percent. This is a 16.21 percent increase over sales of $49.93 million the same period last year.

Mondee Hldgs Q1 Adj $(0.15) Misses $(0.10) Estimate, Sales $58.02M Beat $55.23M Estimate

Needham analyst Quinn Bolton reiterates Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) with a Hold.

Reiteration

CRNC

Needham Reiterates Hold on Cerence

The Company will report these data later today in an oral presentation at Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Baltimore and virtually.

EDIT

Editas Medicine Reports Presentation Of Preclinical Data Demonstrating Several In Vivo Capabilities Towards Developing Transformative In Vivo Gene Editing Medicines

Needham analyst Mike Matson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Hold.

Needham Reiterates Hold on Steris

AIRS

AirSculpt Technologies Sees Fy24 Revenue Of $220M Vs. $219.33M Est.

Needham analyst Matt McGinley maintains Trulieve Cannabis (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) with a Buy and raises the price target from $13.5 to $14.5.

TCNNF

Needham Maintains Buy on Trulieve Cannabis, Raises Price Target to $14.5

Long-term KRESLADI&nbsp;follow-up data demonstrate survival of&nbsp;100%&nbsp;in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety profile in all nine patients with severe LAD-I.
Previously disclosed results from the global RP-L102 Fanconi Anemia Phase 1/2 trial demonstrate genetic and phenotypic correction combined with hematologic stabilization extending to 42 months with polyclonal integration patterns

RCKT

Rocket Pharmaceuticals Presents Longer-Term Data Updates From Its Lentiviral Vector Hematology Portfolio At ASGCT

AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.02) by 250 percent. This is a 70 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $47.62 million which missed the analyst consensus estimate of $49.80 million by 4.38 percent. This is a 3.94 percent increase over sales of $45.81 million the same period last year.

AirSculpt Technologies Q1 Adj $0.03 Beats $(0.02) Estimate, Sales $47.62M Miss $49.80M Estimate

AQB, PHUN and GURE among mid-day movers

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Elicio Therapeutics (ELTX – Research Report), with a price target of $11.00. Rob...

Elicio Therapeutics: A Strong Buy on Breakthrough Immunotherapy Platform and Broad Cancer Treatment Potential

OGEN, SSP and ZENV among mid-day movers

Elicio Therapeutics to sell 1.03M shares $5.81 in private placement financing

Canopy Growth, Outlook Therapeutics, Immuneering among healthcare movers

WIMI, TTNP and STI among mid-day movers

These Healthcare stocks are trading higher:-Chromadex Corp (CDXC) stock is trading at $3.18, a gain of $0.78, or 31.67%, on high volume.  Chromadex Corp CS gets a Sentiment Score of Very Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $5.55.  -Akso Health G

Healthcare Stocks Moving Monday: CDXC, AHG, IMRX, ELTX, CMAX, ABEO, ZJYL, WGS

Elicio Therapeutics GAAP EPS of -$6.96

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Elicio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eltx-stock-quote/">ELTX</a>) just reported results for the fourth quarter of 2023.<ul><li>Elicio Therapeutics reported earnings per share of -$3.77. This was below the analyst estimate for EPS of -78 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/eltx-stock-earnings-elicio-therapeutics-for-q4-of-2023/">ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023

ABEO

AMLX

BBLG

BFRG

CDXC

CETY

CLDI

CMAX

COCH

CREV

CXAI

DWAC

EVAX

FTEL

GDTC

GOEV

GURE

IMRX

LAES

LFLY

MEDS

NEXI

NVEI

NVVE

OGEN

OTLK

PBLA

PCSA

PHUN

RETO

RVSN

SGMT

SOND

SWIN

TCBP

TPHS

TTNP

WIMI

ZENV

ZJYL

Financing

Press Releases

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

Unlocking the Power of Immunotherapy: Elicio Therapeutics' (NASDAQ: ELTX) Novel AMP Platform

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry

Elicio Therapeutics Celebrates 13 Years Developing Innovative Cancer Immunotherapies

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Elicio Therapeutics Stock (NASDAQ:ELTX), Short Interest Report

People Also Watch